Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy

Who May Qualify: - Patients diagnosed histologically with cervical cancer - Patients diagnosed histologically with Squamous cell carcinoma, Adenocarcinoma, or Adenosquamous carcinoma - Patients who have undergone radical hysterectomy and pelvic lymphadenectomy - Patients who meet the indication for radiotherapy in postoperative pathological examination (at least on of the following): A. Pelvic lymph node metastasis B. Parametrial involvement C. Positive surgical margins - Adult aged 20 to 75 years - Patients with an ECOG 0-1 within 1 week prior to study participation - Maintained bone marrow function: granulocyte ≥1.0 x 103/µl, platelet count at least 30 x 103/µl, blood count (hemoglobin) at least 9.5 g/dl - Maintained renal and liver function (Creatinine \<2.0 mg/dL, Bilirubin \< 1.5 mg/dl) - Patients who have voluntarily signed the consent form Who Should NOT Join This Trial: - Patients with distance metastasis (including ovarian and para-aortic lymph node metastasis) - Patients who have previously received radiotherapy to the pelvic area - Patients who have undergone radical hysterectomy more than 3 months prior - Patients with untreated serious acute illnesses (e.g., stroke, cerebral infarction, myocardial infarction) other than cervical cancer - Patients who received neoadjuvant chemotherapy before surgery - Patients who will not receive concurrent chemotherapy during radiotherapy - Patients with a history of another cancer diagnosis within the past 5 years, except for thyroid cancer, skin cancer, or carcinoma in suit Always talk to your doctor about whether this trial is right for you.